211 related articles for article (PubMed ID: 22573348)
21. Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.
Li Q; Ingram L; Kim S; Beharry Z; Cooper JA; Cai H
Neoplasia; 2018 Mar; 20(3):233-243. PubMed ID: 29444487
[TBL] [Abstract][Full Text] [Related]
22. Ectopic fibroblast growth factor receptor 1 promotes inflammation by promoting nuclear factor-κB signaling in prostate cancer cells.
Wang C; Ke Y; Liu S; Pan S; Liu Z; Zhang H; Fan Z; Zhou C; Liu J; Wang F
J Biol Chem; 2018 Sep; 293(38):14839-14849. PubMed ID: 30093411
[TBL] [Abstract][Full Text] [Related]
23. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
[TBL] [Abstract][Full Text] [Related]
24. SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.
Qian B; Yao Y; Liu C; Zhang J; Chen H; Li H
Int J Oncol; 2017 May; 50(5):1601-1611. PubMed ID: 28339027
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.
Maehara O; Suda G; Natsuizaka M; Ohnishi S; Komatsu Y; Sato F; Nakai M; Sho T; Morikawa K; Ogawa K; Shimazaki T; Kimura M; Asano A; Fujimoto Y; Ohashi S; Kagawa S; Kinugasa H; Naganuma S; Whelan KA; Nakagawa H; Nakagawa K; Takeda H; Sakamoto N
Carcinogenesis; 2017 Oct; 38(11):1073-1083. PubMed ID: 28927233
[TBL] [Abstract][Full Text] [Related]
26. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
[TBL] [Abstract][Full Text] [Related]
27. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
Giri D; Ropiquet F; Ittmann M
Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739
[TBL] [Abstract][Full Text] [Related]
28. Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth.
Tarkkonen KM; Nilsson EM; Kähkönen TE; Dey JH; Heikkilä JE; Tuomela JM; Liu Q; Hynes NE; Härkönen PL
PLoS One; 2012; 7(11):e49970. PubMed ID: 23185502
[TBL] [Abstract][Full Text] [Related]
29. AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells.
Yao TJ; Zhu JH; Peng DF; Cui Z; Zhang C; Lu PH
Tumour Biol; 2015 Jul; 36(7):5641-8. PubMed ID: 25691251
[TBL] [Abstract][Full Text] [Related]
30. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
31. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.
Pang X; Yi T; Yi Z; Cho SG; Qu W; Pinkaew D; Fujise K; Liu M
Cancer Res; 2009 Jan; 69(2):518-25. PubMed ID: 19147565
[TBL] [Abstract][Full Text] [Related]
32. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.
Ibuki N; Ghaffari M; Reuveni H; Pandey M; Fazli L; Azuma H; Gleave ME; Levitzki A; Cox ME
Mol Cancer Ther; 2014 Dec; 13(12):2827-39. PubMed ID: 25267499
[TBL] [Abstract][Full Text] [Related]
33. c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.
Liu H; Ai J; Shen A; Chen Y; Wang X; Peng X; Chen H; Shen Y; Huang M; Ding J; Geng M
Clin Cancer Res; 2017 Feb; 23(4):974-984. PubMed ID: 27401245
[No Abstract] [Full Text] [Related]
34. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
Liao Y; Guo Z; Xia X; Liu Y; Huang C; Jiang L; Wang X; Liu J; Huang H
J Exp Clin Cancer Res; 2019 Apr; 38(1):157. PubMed ID: 30975171
[TBL] [Abstract][Full Text] [Related]
36. Effects of FGFR Signaling on Cell Proliferation and Differentiation of Apert Dental Cells.
Lu C; Huguley S; Cui C; Cabaniss LB; Waite PD; Sarver DM; Mamaeva OA; MacDougall M
Cells Tissues Organs; 2016; 201(1):26-37. PubMed ID: 26613250
[TBL] [Abstract][Full Text] [Related]
37. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904
[TBL] [Abstract][Full Text] [Related]
38. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.
Scheller T; Hellerbrand C; Moser C; Schmidt K; Kroemer A; Brunner SM; Schlitt HJ; Geissler EK; Lang SA
Br J Cancer; 2015 Mar; 112(5):841-50. PubMed ID: 25688743
[TBL] [Abstract][Full Text] [Related]
39. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
[TBL] [Abstract][Full Text] [Related]
40. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
SenthilKumar G; Fisher MM; Skiba JH; Miller MC; Brennan SR; Kaushik S; Bradley ST; Longhurst CA; Buehler D; Nickel KP; Iyer G; Kimple RJ; Baschnagel AM
Mol Cancer Ther; 2020 Jun; 19(6):1255-1265. PubMed ID: 32371583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
